隔壁有妈妈说娃爸非要给孩子打疫苗。看看吧！ Pfizer为6/15号的FDA meeting提交的文件： document for the Vaccines and Related Biological Products Advisory Committee Meeting on 6/15 https://www.fda.gov/media/159195/download 第六页复制过来的: "Preliminary descriptive efficacy analyses ......In these analyses, three COVID-19 cases occurred in participants 6-23 months of age, with 1 COVID-19 case in the BNT162b2 group compared to 2 in the placebo group, corresponding to an estimated VE of 75.6% (95% CI: −369.1%, 99.6%), and 7 COVID-19 cases occurred in participants 2-4 years of age, with 2 cases in the BNT162b2 group and 5 in the placebo group, corresponding to an estimated VE of 82.4% (95% CI: −7.6%, 98.3%). In a combined analysis of both age groups, VE was 80.4% (95% CI: 14.1%, 96.7%) with 3 cases in the BNT162b2 group and 7 cases in the placebo group. ......" 就是说，80%的有效率，是基于第三针7天以后到报告截止的10个case计算的，打针组有3粒，对照组有7粒。完全忽视了试验过程中的740（！）个case。就问你服不服。下面表里可以看到从开打到最后每个时间点的case，疫苗组始终都有很多孩子感染，感染率和对照组不相上下（对照组人少），第一针到第二针之间直接是负有效率。最右边是有效率，括号里是confidence interval，每个数值都是从负数开始的，就是说，有有效率是负数的可能，如果真的是负的，那就是打了更可能传上。
还是第六页复制过来的。 "Among all COVID-19 cases accrued from Dose 1 through the data cutoff of April 29, 2022, 1 placebo recipient 6-23 months of age and 7 participants 2-4 years of age (6 BNT162b2 recipients and 1 placebo recipient) met the protocol- specified criteria for severe COVID-19 during both blinded and open-label follow-up. Only one of these severe COVID-19 cases (in a BNT162b2 recipient 99 days post-Dose 2) resulted in hospitalization......" 也就是说，疫苗组一共有6个孩子得了severe covid，对照组2个，疫苗组的6个里还有一个住院了。
The estimated VE for the prevention of COVID-19 disease after Dose 1 in the all-available efficacy population is 14.0% (95% CI: -21.2%-38.3%) for participants 6-23 months of age and 32.6% (95% CI: 10.8%-48.8%) for participants 2-4 years of age Page 40
隔壁有妈妈说娃爸非要给孩子打疫苗。看看吧！ Pfizer为6/15号的FDA meeting提交的文件： document for the Vaccines and Related Biological Products Advisory Committee Meeting on 6/15 https://www.fda.gov/media/159195/download 第六页复制过来的: "Preliminary descriptive efficacy analyses ......In these analyses, three COVID-19 cases occurred in participants 6-23 months of age, with 1 COVID-19 case in the BNT162b2 group compared to 2 in the placebo group, corresponding to an estimated VE of 75.6% (95% CI: −369.1%, 99.6%), and 7 COVID-19 cases occurred in participants 2-4 years of age, with 2 cases in the BNT162b2 group and 5 in the placebo group, corresponding to an estimated VE of 82.4% (95% CI: −7.6%, 98.3%). In a combined analysis of both age groups, VE was 80.4% (95% CI: 14.1%, 96.7%) with 3 cases in the BNT162b2 group and 7 cases in the placebo group. ......" 就是说，80%的有效率，是基于第三针7天以后到报告截止的10个case计算的，打针组有3粒，对照组有7粒。完全忽视了试验过程中的740（！）个case。就问你服不服。下面表里可以看到从开打到最后每个时间点的case，疫苗组始终都有很多孩子感染，感染率和对照组不相上下（对照组人少），第一针到第二针之间直接是负有效率。最右边是有效率，括号里是confidence interval，每个数值都是从负数开始的，就是说，有有效率是负数的可能，如果真的是负的，那就是打了更可能传上。
还是第六页复制过来的。 "Among all COVID-19 cases accrued from Dose 1 through the data cutoff of April 29, 2022, 1 placebo recipient 6-23 months of age and 7 participants 2-4 years of age (6 BNT162b2 recipients and 1 placebo recipient) met the protocol- specified criteria for severe COVID-19 during both blinded and open-label follow-up. Only one of these severe COVID-19 cases (in a BNT162b2 recipient 99 days post-Dose 2) resulted in hospitalization......" 也就是说，疫苗组一共有6个孩子得了severe covid，对照组2个，疫苗组的6个里还有一个住院了。
以前5-11小孩的有效率，很短的时间就wane到12%，看看这回小小孩的三针能撑多久。。。 The vaccine''s efficacy against infection among those children declined to 12% at the end of January from 68% in mid-December compared to kids who did not get vaccinated
HORRORS Obama's FDA Purchased 'Fresh and Never Frozen' Aborted Baby Heads and Other Body Parts https://rumble.com/v1a5thn-horrors-obamas-fda-purchased-fresh-and-never-frozen-aborted-baby-heads-and-.html FDA是个什么组织？
来。我来解释一下80% 是怎么来的。不要被不懂统计的人危言耸听。文章里面原话： Preliminary descriptive efficacy analyses of COVID-19 cases occurring at least 7 days post- Dose 3 included 376 BNT162b2 recipients and 179 placebo recipients 6-23 months of age and 589 BNT162 recipients and 271 placebo recipients 2-4 years of age. In these analyses, three COVID-19 cases occurred in participants 6-23 months of age, with 1 COVID-19 case in the BNT162b2 group compared to 2 in the placebo group, corresponding to an estimated VE of 75.6% (95% CI: −369.1%, 99.6%), and 7 COVID-19 cases occurred in participants 2-4 years of age, with 2 cases in the BNT162b2 group and 5 in the placebo group, corresponding to an estimated VE of 82.4% (95% CI: −7.6%, 98.3%). In a combined analysis of both age groups, VE was 80.4% (95% CI: 14.1%, 96.7%) with 3 cases in the BNT162b2 group and 7 cases in the placebo group. Cases were accrued during February 2022 through April 2022, when the Omicron variant was prevalent in the United States. Among all COVID-19 cases accrued from Dose 1 through the data cutoff of April 29, 2022, 1 placebo recipient 6-23 months of age and 7 participants 2-4 years of age (6 BNT162b2 recipients and 1 placebo recipient) met the protocol- specified criteria for severe COVID-19 during both blinded and open-label follow-up. Only one of these severe COVID-19 cases (in a BNT162b2 recipient 99 days post-Dose 2) resulted in hospitalization, and the remainder met criteria for severe COVID-19 based on vital sign findings that were not clinically significant in the opinion of the investigator and FDA.
Pfizer为6/15号的FDA meeting提交的文件： document for the Vaccines and Related Biological Products Advisory Committee Meeting on 6/15
https://www.fda.gov/media/159195/download
第六页复制过来的:
"Preliminary descriptive efficacy analyses ......In these analyses, three COVID-19 cases occurred in participants 6-23 months of age, with 1 COVID-19 case in the BNT162b2 group compared to 2 in the placebo group, corresponding to an estimated VE of 75.6% (95% CI: −369.1%, 99.6%), and 7 COVID-19 cases occurred in participants 2-4 years of age, with 2 cases in the BNT162b2 group and 5 in the placebo group, corresponding to an estimated VE of 82.4% (95% CI: −7.6%, 98.3%). In a combined analysis of both age groups, VE was 80.4% (95% CI: 14.1%, 96.7%) with 3 cases in the BNT162b2 group and 7 cases in the placebo group. ......"
就是说，80%的有效率，是基于第三针7天以后到报告截止的10个case计算的，打针组有3粒，对照组有7粒。完全忽视了试验过程中的740（！）个case。就问你服不服。下面表里可以看到从开打到最后每个时间点的case，疫苗组始终都有很多孩子感染，感染率和对照组不相上下（对照组人少），第一针到第二针之间直接是负有效率。最右边是有效率，括号里是confidence interval，每个数值都是从负数开始的，就是说，有有效率是负数的可能，如果真的是负的，那就是打了更可能传上。
还是第六页复制过来的。
"Among all COVID-19 cases accrued from Dose 1 through the data cutoff of April 29, 2022, 1 placebo recipient 6-23 months of age and 7 participants 2-4 years of age (6 BNT162b2 recipients and 1 placebo recipient) met the protocol- specified criteria for severe COVID-19 during both blinded and open-label follow-up. Only one of these severe COVID-19 cases (in a BNT162b2 recipient 99 days post-Dose 2) resulted in hospitalization......"
也就是说，疫苗组一共有6个孩子得了severe covid，对照组2个，疫苗组的6个里还有一个住院了。
打了还可能更容易传染，之后还可能更容易重症，之外还要承担长期副作用不明的风险，这打个毛线啊？
系统提示：若遇到视频无法播放请点击下方链接
https://www.youtube.com/embed/3ICBBK-d-C0?showinfo=0
thanks，enjoyed seeing Fauci getting drilled this way
前几天的讨论有链接吗？
Page 40
VE vaccine efficacy
这药厂也太黑了吧，简直了。。。。。
The vaccine''s efficacy against infection among those children declined to 12% at the end of January from 68% in mid-December compared to kids who did not get vaccinated
黑色幽默🥷
前几天的讨论链接？能不能把结论，论点，论据都贴出来再来大惊小怪的说别人“大惊小怪的断章取义”啊？
可以看看我以前的帖子。。。。。
https://huaren.us/showtopic.html?topicid=2818516&postid=93617915#93617915
这个帖子里小浣熊后面对这个数据有解读分析。当然，不信她说的，也别跟我争，我也没那个空跟你磨嘴皮子
Preliminary descriptive efficacy analyses of COVID-19 cases occurring at least 7 days post- Dose 3 included 376 BNT162b2 recipients and 179 placebo recipients 6-23 months of age and 589 BNT162 recipients and 271 placebo recipients 2-4 years of age. In these analyses, three COVID-19 cases occurred in participants 6-23 months of age, with 1 COVID-19 case in the BNT162b2 group compared to 2 in the placebo group, corresponding to an estimated VE of 75.6% (95% CI: −369.1%, 99.6%), and 7 COVID-19 cases occurred in participants 2-4 years of age, with 2 cases in the BNT162b2 group and 5 in the placebo group, corresponding to an estimated VE of 82.4% (95% CI: −7.6%, 98.3%). In a combined analysis of both age groups, VE was 80.4% (95% CI: 14.1%, 96.7%) with 3 cases in the BNT162b2 group and 7 cases in the placebo group. Cases were accrued during February 2022 through April 2022, when the Omicron variant was prevalent in the United States. Among all COVID-19 cases accrued from Dose 1 through the data cutoff of April 29, 2022, 1 placebo recipient 6-23 months of age and 7 participants 2-4 years of age (6 BNT162b2 recipients and 1 placebo recipient) met the protocol- specified criteria for severe COVID-19 during both blinded and open-label follow-up. Only one of these severe COVID-19 cases (in a BNT162b2 recipient 99 days post-Dose 2) resulted in hospitalization, and the remainder met criteria for severe COVID-19 based on vital sign findings that were not clinically significant in the opinion of the investigator and FDA.
实验组总共965人，对照组总共450 人。 实验组有3个cases， 就是有3人得了covid。 所以实验组的中奖率是3/965 ，约为0.31%吧。 对照组有7人中奖，所以中奖率是7/450， 约为1.56%吧。 那么实验组的中奖率比对照组低了1.25%，因为1.56-0.31 =1.25呀。 那么相对于对照组，就得到疫苗的有效率了： 1.25/1.56， 约80%。 我这里是约，因为统计软件计算时，小数位更精确。
lz说80%只考虑了10个case是不正确的。 上面的计算还包括了covid 阴性的人。
爱说谎的世卫